|
Volumn 44, Issue 6, 2007, Pages 887-888
|
Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency [3]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMPRENAVIR PHOSPHATE;
ANTIRETROVIRUS AGENT;
COTRIMOXAZOLE;
HEMOGLOBIN;
PRIMAQUINE;
PROTEINASE INHIBITOR;
ANEMIA;
ANTIBIOTIC PROPHYLAXIS;
CD4 LYMPHOCYTE COUNT;
COMBINATION CHEMOTHERAPY;
DRUG INDUCED DISEASE;
DRUG SAFETY;
FEMALE;
GLYCOGEN STORAGE DISEASE TYPE 1;
HEMOGLOBIN BLOOD LEVEL;
HEMOGLOBIN DETERMINATION;
HEMOLYTIC ANEMIA;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LETTER;
MAJOR CLINICAL STUDY;
MALE;
PNEUMOCYSTIS PNEUMONIA;
PRIORITY JOURNAL;
SIDE EFFECT;
TREATMENT OUTCOME;
CARBAMATES;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
DRUG THERAPY, COMBINATION;
FEMALE;
FOLLOW-UP STUDIES;
GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY;
HEMOGLOBINS;
HIV INFECTIONS;
HIV PROTEASE INHIBITORS;
HUMANS;
MALE;
PHOSPHORIC ACID ESTERS;
PROBABILITY;
RETROSPECTIVE STUDIES;
RISK FACTORS;
SULFONAMIDES;
TREATMENT OUTCOME;
|
EID: 33847642687
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/511881 Document Type: Letter |
Times cited : (3)
|
References (5)
|